Clinically Reviewed by Bobby Boykin, MS, LASAC, CRS
Is 7-OH addictive? Yes. 7-OH, short for 7-hydroxymitragynine, acts on the same mu-opioid receptors that morphine and oxycodone act on, which means regular use can build tolerance, physical dependence, and opioid-type withdrawal. The Food and Drug Administration describes it plainly as an opioid that can be more potent than morphine, and as a concentrated byproduct of the kratom plant rather than the leaf itself.
That gap between how 7-OH is sold and what it does is the reason people are caught off guard. It is sold in tablets, gummies, drink mixes, and shots at gas stations, vape shops, and online. Nothing about that shelf placement changes the pharmacology, and men who started with a product marketed as an energy or focus aid often find themselves taking it several times a day within a matter of weeks.
If you or someone you know is in a medical emergency, call 911. The 988 Suicide and Crisis Lifeline is available 24/7 by call or text. Naloxone can reverse an opioid overdose if it is given in time, and 7-OH is an opioid. If you have been using heavily and are thinking about stopping, talk with a medical professional first rather than stopping on your own. For what to do in the moment, see how to respond to a drug overdose.
This article is general information and not medical advice. Do your own research and speak with a qualified professional about your situation.
Key things to know
- 7-OH is an opioid-receptor agonist, not a mild herbal supplement.
- Concentrated 7-OH products deliver far more of the compound than the kratom leaf it is derived from.
- Tolerance and physical dependence can develop within weeks of regular use.
- Withdrawal is opioid-type, and it is a medical matter rather than a test of willpower.
- Guiding Road does not provide detox on site. Medical needs are coordinated with medical partners.
What 7-OH actually is
7-hydroxymitragynine is a minor alkaloid associated with kratom, the plant Mitragyna speciosa. Kratom leaf is dominated by a different alkaloid, mitragynine, and 7-OH occurs naturally in the leaf only in trace amounts. The products now sold under the 7-OH name are different. They concentrate or semi-synthesize that trace compound into tablets, gummies, drink mixes, and shots, which is why the FDA treats them as a separate problem from the leaf.
From kratom leaf to concentrated product
The distinction matters more than the shared name suggests. Research describes 7-OH as a mu-opioid receptor agonist that is substantially more potent at those receptors than morphine, present naturally in very small amounts and enriched deliberately in high-potency products. In July 2025 the FDA recommended that 7-OH be scheduled under the Controlled Substances Act and issued warning letters to companies marketing concentrated 7-OH tablets, gummies, drink mixes, and shots. A person who has used kratom tea for years and a person taking pressed 7-OH tablets through the day are not doing the same thing.
Why “plant-based” and “legal” do not mean low risk
Legal status is a regulatory fact, not a safety rating. As of August 2026, 7-OH’s federal status is in motion. The Drug Enforcement Administration published notices of intent on July 6, 2026 to temporarily place 7-OH above a specified threshold into Schedule I, with the threshold set at 0.05 percent or 1 milligram per article for processed forms such as extracts and pressed pills, and stated that a temporary order could publish on or after August 5, 2026 and would take effect the day it publishes. Botanical kratom leaf below that threshold is not covered. Check the current federal and Arizona status before relying on any of this, because it is changing.
Why dependence forms so fast
Dependence on 7-OH forms quickly for three reasons that compound each other: the compound is a potent opioid-receptor agonist, the products are concentrated and taken repeatedly through the day, and there is no prescriber watching the pattern. Together those conditions shorten the runway from first use to needing the substance simply to feel normal.
Receptor activity and potency
7-OH binds the mu-opioid receptor, the same receptor prescription opioids act on. That is the whole explanation for why the body adapts the way it does. Repeated activation of that receptor produces tolerance, and tolerance produces escalation. The FDA’s own characterization, an opioid that can be more potent than morphine, is the reason clinicians treat 7-OH dependence as opioid dependence rather than as a supplement habit.
How tolerance builds
Tolerance means the same amount produces less effect over time, so a person needs more to reach what he felt before. It is a physiological adaptation, not a character flaw, and it happens whether the substance came from a pharmacy or a checkout counter.
Dependence is not the same as addiction
Physical dependence means the body has adapted and withdrawal follows if the substance stops. Addiction, clinically a use disorder, adds loss of control and continued use despite harm. A person can be physically dependent without having a use disorder, and both are treatable.
Product form and dosing frequency
Form drives frequency. A tablet, a gummy, or a shot is easy to take again, and easy to take at work, in a car, or between errands. Because the effect is short of a full day, use tends to spread across waking hours rather than sitting at one point in it. Repeated daily exposure is exactly the pattern that produces tolerance fastest, which is why men often describe the shift from occasional to constant as taking weeks rather than years.
Availability and the absence of a prescriber
With a prescribed opioid there is a clinician tracking the amount, the duration, the interactions, and the escalation. With an over-the-counter 7-OH product there is nobody in that role. No one is counting, no one is asking, and no one is checking what else a person takes alongside it. That absence is a risk factor in its own right, separate from the pharmacology.
The scale of the problem shows up in poison-center data. Kratom-related reports to United States poison centers rose from 258 in 2015 to 3,434 in 2025, an increase of about 1,200 percent, with 14,449 reports over the 11-year period, according to the Centers for Disease Control and Prevention. The same report counted 233 deaths across the period, 79 percent of which involved more than one substance, and 1,087 hospitalizations in 2025. The CDC notes the 2025 surge coincided with the emergence of high-potency, semisynthetic formulations, and also notes the data do not separate leaf products from concentrates.
Get Help for Substance Abuse at Guiding Road
What 7-OH withdrawal looks like
7-OH withdrawal is opioid-type withdrawal. Because the compound acts at the mu-opioid receptor, stopping after regular use tends to produce the same cluster clinicians see with other opioids: restlessness, muscle and joint aches, sweating and chills, nausea or stomach upset, insomnia, anxiety and irritability, and strong cravings. Timing varies with how much and how long a person has used, and with anything else he is taking.
Why stopping alone is risky
Opioid withdrawal is rarely life threatening on its own, but stopping alone still carries real risk. Vomiting and diarrhea can leave a person dehydrated. Anxiety, insomnia, and low mood are harder to manage without support, and they are harder still for someone already living with a co-occurring mental health condition. The most serious risk is what follows a return to use after a break, when tolerance has dropped and a familiar amount is no longer familiar to the body. Talk with a medical professional about how to stop rather than working out a taper on your own. Guiding Road does not provide detox on site, and coordinates it as specialty care with medical partners. You can read more about medical detox for 7-hydroxymitragynine.
Common myths about 7-OH
Myth: it is sold over the counter, so it cannot be addictive
Retail availability reflects regulation, not pharmacology. The FDA describes 7-OH as an opioid that can be more potent than morphine and has recommended scheduling it. Where a product sits on a shelf says nothing about what it does at the receptor.
Myth: it is just kratom
7-OH occurs in the kratom leaf in trace amounts. The products sold under its name are concentrated or semi-synthesized, so they deliver far more of a far more potent compound than leaf preparations do. The FDA treats concentrated 7-OH products as distinct from botanical kratom.
Myth: needing it to feel normal means it is working
Needing a substance to avoid feeling unwell is physical dependence, a recognized clinical state, not evidence of benefit. When a dose stops producing an effect and only prevents withdrawal, the body has adapted, and that is a reason to talk with a professional.
Myth: quitting is just a matter of willpower
Opioid-type use disorder is a treatable medical condition with a physiological basis. Withdrawal is a bodily process, not a moral test. Treatment exists because willpower alone does not resolve receptor-level adaptation, and asking for help is a clinical step rather than a concession.
When to reach out for help
There is no single sign that settles the question, and only a professional assessment can confirm a use disorder. What is worth paying attention to is the pattern rather than any one incident.
Signs it is time to talk to a professional
- Using primarily to avoid feeling sick rather than for any effect he wanted
- Taking more, or more often, than he did a month or two ago
- Repeated attempts to stop or cut back that do not hold
- Keeping purchases or use hidden from people close to him
- Continuing despite money strain, work problems, or conflict at home
If you are the wife, parent, or friend reading this, the same pattern is what you are looking at from the outside. You do not need certainty to start a conversation, and you do not need to diagnose anyone to ask how he is doing.
What treatment for 7-OH dependence involves
Care usually starts with medical stabilization, coordinated with medical partners rather than delivered on site here, and continues into structured treatment. Guiding Road is a men-only program in the Phoenix, Arizona metro offering residential treatment, a partial hospitalization program, and an intensive outpatient program, and it is accredited by the Joint Commission for behavioral health care. Medication for opioid use disorder, including buprenorphine, methadone, and naltrexone, is evidence-based care for opioid use disorder and is available at programs that provide it. Guiding Road’s program is abstinence-based and 12-step-immersive and does not offer medication-assisted treatment, so which approach fits is worth talking through honestly with an admissions team. You can read more about 7-OH addiction treatment and about inpatient 7-OH treatment for men. Recovery outcomes vary by individual, program, and level of engagement.
Common questions about 7-OH
Is 7-OH an opioid?
Yes. 7-hydroxymitragynine acts as an agonist at the mu-opioid receptor, the same receptor prescription opioids act on. The FDA describes it as an opioid that can be more potent than morphine. Being derived from a plant does not place it outside the opioid class.
How long does it take to become dependent on 7-OH?
There is no fixed number, and it depends on how much a person uses, how often, and for how long. With concentrated products taken several times a day, tolerance and physical dependence commonly develop within weeks rather than months, which is faster than many people expect from an over-the-counter product.
What are 7-OH withdrawal symptoms?
Withdrawal is opioid-type: restlessness, muscle aches, sweating and chills, nausea or stomach upset, insomnia, anxiety, irritability, and strong cravings. Severity tracks how heavily and how long a person has used. Anyone stopping after heavy use should talk with a medical professional first.
Is 7-OH legal?
Its status is changing. As of August 2026, the DEA has published notices of intent to temporarily place 7-OH above a specified threshold into Schedule I, with an order possible on or after August 5, 2026, and some states have acted separately. Check the current federal and state status before relying on any summary.
Is 7-OH the same as kratom?
No. 7-OH is a trace alkaloid associated with the kratom plant, and the products sold under its name concentrate or semi-synthesize it. That makes them substantially more potent than leaf preparations, which is why the FDA and the DEA have treated concentrated 7-OH products separately from botanical kratom.
Can 7-OH dependence be treated?
Yes. Because 7-OH dependence is opioid dependence, it responds to the same care pathways: medical stabilization first, then structured treatment that addresses substance use alongside any co-occurring mental health conditions. Options range from residential care to intensive outpatient, matched to how much structure a person needs.
If you are trying to work out the next step for yourself or for a man in your life, Guiding Road’s admissions team can talk it through with you. Call (480) 588-2328, or talk with the admissions team. Insurance coverage varies by plan, and the admissions team can review your specific benefits when you call.
Key Takeaways
- 7-OH is an opioid. It acts at the mu-opioid receptor, and the FDA describes it as an opioid that can be more potent than morphine.
- Concentrates are not the leaf. 7-OH occurs in kratom leaf in trace amounts, while marketed tablets, gummies, and shots concentrate or semi-synthesize it.
- Dependence forms fast. Potency, repeated daily dosing, and no prescriber tracking escalation combine to shorten the path from occasional use to daily need.
- Withdrawal is opioid-type. Restlessness, aches, sweating, nausea, insomnia, anxiety, and cravings are common, and stopping should be discussed with a medical professional.
- It is treatable. Detox is coordinated with medical partners, and structured care follows. Recovery outcomes vary by individual, program, and level of engagement.
Sources
- U.S. Food and Drug Administration. (2025). FDA Takes Steps to Restrict 7-OH Opioid Products Threatening American Consumers. FDA. https://www.fda.gov/news-events/press-announcements/fda-takes-steps-restrict-7-oh-opioid-products-threatening-american-consumers
- U.S. Food and Drug Administration. (2025). 7-Hydroxymitragynine (7-OH): An Assessment of the Scientific Data and Toxicological Concerns Around an Emerging Opioid Threat. FDA. https://www.fda.gov/files/drugs/published/7-hydroxymitragynin_7-oh_an_assessment_of_the_scientific_data_and_toxicological_concerns_around_an_emerging_opioid_threat.pdf
- Drug Enforcement Administration. (2026). Schedules of Controlled Substances: Temporary Placement of 7-Hydroxymitragynine Above a Specified Threshold in Schedule I. Federal Register, 91 FR 40917. https://www.federalregister.gov/documents/2026/07/06/2026-13580/
- Centers for Disease Control and Prevention. (2026). Increases in Kratom-Related Reports to Poison Centers, National Poison Data System, United States, 2015 to 2025. MMWR, 75(11). https://www.cdc.gov/mmwr/volumes/75/wr/mm7511a1.htm
- National Institute on Drug Abuse. (2025). Kratom. NIDA. https://nida.nih.gov/research-topics/kratom
- Substance Abuse and Mental Health Services Administration. (2025). Medications for Substance Use Disorders. SAMHSA. https://www.samhsa.gov/medications-substance-use-disorders